Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
141.54
+0.08 (+0.06%)
Official Closing Price
Updated: 7:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
53
54
Next >
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
2 Dividend Growth Stocks to Buy and Hold Forever
↗
June 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
↗
June 05, 2025
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”
Via
Stocktwits
Topics
ETFs
Is Novartis Gaining or Losing Market Support?
↗
June 04, 2025
Via
Benzinga
Earnings Scheduled For April 29, 2025
↗
April 29, 2025
Via
Benzinga
Earnings Preview For Novartis
↗
April 28, 2025
Via
Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
↗
May 29, 2025
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
May 28, 2025
Via
Benzinga
The Smartest Vanguard ETF to Buy With $500 Right Now
↗
May 21, 2025
Via
The Motley Fool
Topics
ETFs
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years
↗
May 16, 2025
This company stands to benefit from the advances in artificial intelligence more than any other business.
Via
The Motley Fool
Topics
Artificial Intelligence
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks
↗
May 15, 2025
IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors.
Via
Benzinga
Topics
ETFs
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
↗
May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via
Benzinga
Here's My Favorite High-Dividend ETF to Buy Right Now
↗
May 14, 2025
Via
The Motley Fool
Topics
ETFs
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
↗
May 12, 2025
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...
Via
Stocktwits
Topics
ETFs
Government
Stocks
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
↗
May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via
Investor's Business Daily
Topics
Government
Stocks
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
↗
May 09, 2025
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via
Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
↗
May 06, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via
Benzinga
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
↗
May 05, 2025
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.
Via
Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
↗
May 01, 2025
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...
Via
Stocktwits
Topics
Stocks
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
↗
April 30, 2025
Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.
Via
Benzinga
Topics
Earnings
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
↗
April 30, 2025
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.
Via
Benzinga
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition
↗
April 30, 2025
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying.
Via
Stocktwits
Topics
Artificial Intelligence
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis
↗
April 30, 2025
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.
Via
Stocktwits
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
↗
April 29, 2025
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales.
Via
Benzinga
Topics
Earnings
Novartis Creeps Toward A Breakout On Its Beat-And-Raise
↗
April 29, 2025
Shares are consolidating and are now trading above their 50-day and 200-day lines.
Via
Investor's Business Daily
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
↗
April 29, 2025
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this...
Via
Benzinga
General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday
↗
April 29, 2025
Via
Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
↗
April 28, 2025
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...
Via
Stocktwits
Topics
Government
Intellectual Property
Lawsuit
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
April 28, 2025
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Government
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
53
54
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today